Adaptive design in clinical research: Issues, opportunities, and recommendations

Journal of Biopharmaceutical Statistics

Volumn 16, Issue 3, 2006, Pages 299-309

  Chang, Mark ^a   Chow, Shein Chung ^b   Pong, Annpey ^c  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

Adaptive design; Drop losers design; Seamless design; Sequential design; Trial simulation

Indexed keywords

DRUG;

ADAPTIVE DESIGN; ARTICLE; CLINICAL RESEARCH; CONFIDENCE INTERVAL; DRUG DESIGN; EPIDEMIOLOGY; PRIORITY JOURNAL; SIMULATION; VALIDATION PROCESS;

BAYES THEOREM; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; GUIDELINES; HUMANS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 33646243834     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400600609718     Document Type: Article

References (17)

1. Bauer, P., Kohne, K. (1994). Evaluation of experiments with adaptive interim analysis. Biometrics 50:1029-1041.
2. Bauer, P., Rohmel, J. (1995). An adaptive method for establishing a dose-response relationship. Stat. Med. 14:1595-1607.
3. Chang, M. (2005). Adaptive clinical trial design. In: Janssen, J., Lenca, P., eds. Proceedings of the XIth International Symposium on Applied Stochastic Models and Data Analysis. ISBN: 2-908849-15-1, Brest, France, ENST Bretagne.
4. Chang, M., Chow, S. C. (2006). An innovative approach in clinical development - utilization of adaptive design methods in clinical trials (submitted for publication).
5. Chow, S. C., Chang, M., Pong, A. (2005). Statistical consideration of adaptive methods in clinical development. J. Biopharm. Stat. 15:575-591.
6. Cui, L., Hung, H. M. J., Wang, S. J. (1999). Modification of sample size in group sequential trials. Biometrics 55:853-857.
7. Ellenberg, S. S., Fleming, T. R., Demets, D. L. (2002). Data Monitoring Committees in Clinical Trials. London: John Wiley & Sons Ltd.
8. EMEA (2002). Point to consider on methodological issues in confirmatory clinical trials with flexible design and analysis plan. London: The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. CPMP/EWP/2459/02.
9. Lehmacher, W., Wassmer, G. (1999). Adaptive sample size calculations in group-sequential trials. Biometrics 55:1286-1290.
10. Liu, Q., Chi, G. Y. H. (2001). On sample size and inference for two-stage adaptive designs. Biometrics 57:172-177.
11. Pocock, S. (2005). When (not) to stop a clinical trial for benefit. JAMA 294:2228-2230.
12. Posch, M., Bauer, P. (2000). Interim analysis and sample size reassessment. Biometrics 56:1170-1176.
13. Proschan, M. A., Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51:1315-1324.
14. Sampson, A. R., Sill, M. W. (2005). Drop-the-loser design: Normal case. Biom. J. 3:257-268.
15. Stewart, W., Ruberg, S. J. (2000). Detecting dose response with contrasts. Stat. Med. 19:913-921.
16. Wassmer, G. (1999). Multistage adaptive test procedures based on Fisher's product criterion. Biom. J. 41:279-293.
17. Woodcock, J. (2004). FDA's Critical Path Initiative. FDA website: http://www.fda.gov/oc/initiatives/criticalpath/woodcock0602/woodcock0602.html